23h agoInvestors.comBULLISH 63General
Nasdaq Breaks Out To New Highs; Shopify, Taiwan Semiconductor, Guardant Health In Focus
Alissa Coram and Rachel Fox walk through Monday's market action and discuss key stocks to watch in Stock Market Today.
Archived explainer. For the current picture see today's GH page.
Why Is GUARDANT HEALTH INC (GH) Stock Down Today?
By the Top Tier Newswire AI Desk · October 6, 2026 at 11:11 AM ET · reviewed against 3 wire stories
GUARDANT HEALTH INC (GH) is down -6.53% in the latest session. Our newswire has captured 3 stories on GH across 3 sources in the last 36 hours, with AI sentiment reading bullish (avg 64/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Why GH stock is down today
Guardant Health Inc stock fell 6.53% to $175.04 in afternoon trading on Monday after opening near its 52-week high. The decline followed the release of data from the company’s COSMOS-MEL01 trial, which showed 81% sensitivity for predicting distant recurrence in melanoma using its liquid biopsy test. The stock’s sharp intraday pullback came despite recent positive coverage and a string of analyst upgrades.
What Happened
The stock opened at $187.62 and briefly climbed to $191.05 before falling to a session low of $174.08. The decline followed the publication of the COSMOS study in *Cancer Research Communications*, which validates the utility of Guardant Reveal™ for predicting recurrence in melanoma. While the data is a scientific milestone, the market appeared to price in concerns about broader commercial adoption or competitive dynamics. The stock traded at a discount to its 52-week high of $187.69 and has now pulled back from recent gains.
What The Data Shows
The stock has traded in a wide 52-week range of $61.00 to $187.69 and has shown a strong revenue growth rate of 42.7% in the trailing twelve months. However, it remains unprofitable with an EPS of -3.50 and a net margin of -38.3%. The intraday volume of 0.8 million shares was above the 3-month average by 40%. Over the past 8 sessions, the stock had risen 4.8% from $176.07 to $184.57. Recent insider transactions show 12 sales totaling $30.7 million in the last 90 days, with three directors selling shares on September 16.
What To Watch
The stock is currently trading near its 52-week low. Investors may look for a potential earnings report or further analyst commentary in the coming weeks to gauge the market’s reaction to the COSMOS trial results.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
GH by the numbers
Last: $175.00Session: -6.53%7 sessions: +4.83%Coverage: 3 stories / 3 sourcesAI sentiment: 64/100 (bullish)Mkt cap: $23.9B52w: $61.00 to $187.69
The headlines behind the move
1d agoThe FlyBULLISH 63Product/PR
Guardant Health reports COSMOS study published in Cancer Research Communications
1d agoStockTitanBULLISH 67Product/PR
Guardant Health COSMOS Study Published in Cancer Research Communications Validates Utility of Guardant Reveal™ Liquid Biopsy Test for Predicting Recurrence in Melanoma
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on GH: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier GH move explainers: 2026-10-06